TXG
10x Genomics, Inc. NASDAQ Listed Sep 12, 2019$22.41
Mkt Cap $2.9B
52w Low $8.06
78.0% of range
52w High $26.45
50d MA $21.51
200d MA $17.09
P/E (TTM)
-64.1x
EV/EBITDA
-15.5x
P/B
3.5x
Debt/Equity
0.2x
ROE
-5.5%
P/FCF
15.6x
RSI (14)
—
ATR (14)
—
Beta
2.17
50d MA
$21.51
200d MA
$17.09
Avg Volume
2.6M
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
6230 Stoneridge Mall Road · Pleasanton, CA 94588-3260 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -0.29 | -0.10 | +65.5% | 22.42 | -6.0% | -3.7% | — | — | — | — | — |
| Feb 12, 2026 | AMC | -0.19 | -0.13 | +31.6% | 17.51 | +9.9% | +3.5% | +6.3% | +11.8% | +9.6% | +7.8% | — |
| Nov 6, 2025 | AMC | -0.07 | -0.22 | -214.3% | 13.00 | +10.1% | +17.3% | +31.4% | +27.6% | +28.4% | +25.8% | — |
| Aug 7, 2025 | AMC | -0.35 | 0.28 | +180.0% | 12.80 | +13.2% | -4.0% | -3.8% | +0.1% | +6.0% | +3.4% | — |
| May 8, 2025 | AMC | -0.45 | -0.36 | +20.0% | 8.63 | +12.5% | +1.6% | +10.0% | +11.8% | +5.7% | +6.6% | — |
| Feb 12, 2025 | AMC | -0.29 | -0.40 | -37.9% | 12.00 | -7.1% | -0.5% | +2.7% | +0.6% | +0.8% | -3.7% | — |
| Oct 29, 2024 | AMC | -0.34 | -0.30 | +11.8% | 15.79 | -2.7% | +4.4% | +1.5% | +3.4% | +6.3% | +9.8% | — |
| Aug 8, 2024 | AMC | -0.47 | -0.32 | +31.9% | 19.55 | +9.7% | +4.5% | +0.5% | +10.1% | +1.1% | +15.8% | — |
| Apr 30, 2024 | AMC | -0.46 | -0.50 | -8.7% | 29.28 | -9.5% | -8.1% | -10.2% | -6.1% | -6.9% | -10.7% | — |
| Feb 15, 2024 | AMC | -0.36 | -0.41 | -13.9% | 48.07 | -2.0% | +0.8% | -1.3% | -3.0% | -5.2% | -6.4% | — |
| Nov 2, 2023 | AMC | -0.45 | -0.51 | -13.3% | 36.53 | -1.5% | +8.7% | +5.8% | +6.8% | +3.8% | -0.1% | — |
| Aug 3, 2023 | AMC | -0.39 | -0.53 | -35.9% | 58.49 | -3.8% | -4.2% | -4.8% | -7.3% | -10.5% | -11.2% | — |
| May 3, 2023 | AMC | -0.38 | -0.44 | -15.8% | 54.00 | +4.1% | +1.3% | +0.5% | +0.9% | -1.4% | +0.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 20 | BofA Securities | Maintains | Neutral → Neutral | — | $26.08 | $25.85 | -0.9% | -5.7% | -11.9% | -12.5% | -17.9% | -15.3% |
| Apr 20 | Canaccord Genuity | Maintains | Buy → Buy | — | $26.08 | $25.85 | -0.9% | -5.7% | -11.9% | -12.5% | -17.9% | -15.3% |
| Apr 14 | Barclays | Maintains | Overweight → Overweight | — | $23.58 | $24.19 | +2.6% | +5.2% | +7.5% | +7.0% | +10.6% | +4.3% |
| Apr 7 | Citigroup | Maintains | Neutral → Neutral | — | $21.89 | $21.77 | -0.5% | -0.3% | +5.2% | +5.1% | +6.3% | +7.7% |
| Mar 31 | William Blair | Upgrade | Market Perform → Outperform | — | $19.81 | $21.00 | +6.0% | +7.2% | +11.3% | +12.7% | +10.5% | +10.1% |
| Mar 2 | Stifel | Maintains | Buy → Buy | — | $23.05 | $22.43 | -2.7% | +0.4% | -1.9% | -3.0% | -6.1% | -9.7% |
| Feb 20 | UBS | Maintains | Neutral → Neutral | — | $19.19 | $19.15 | -0.2% | -1.6% | -1.6% | -0.5% | +2.4% | +15.3% |
| Feb 13 | TD Cowen | Maintains | Hold → Hold | — | $17.51 | $19.24 | +9.9% | +3.5% | +6.3% | +11.8% | +9.6% | +7.8% |
| Feb 13 | Stifel | Maintains | Buy → Buy | — | $17.51 | $19.24 | +9.9% | +3.5% | +6.3% | +11.8% | +9.6% | +7.8% |
| Jan 27 | Leerink Partners | Maintains | Market Perform → Market Perform | — | $22.50 | $22.06 | -2.0% | -3.9% | -6.3% | -7.6% | -10.2% | -11.3% |
| Jan 16 | Leerink Partners | Maintains | Market Perform → Market Perform | — | $21.20 | $21.20 | +0.0% | -3.2% | +4.0% | +7.0% | +9.4% | +5.6% |
| Jan 7 | Leerink Partners | Maintains | Market Perform → Market Perform | — | $19.31 | $19.15 | -0.8% | +3.5% | -0.1% | +6.0% | +2.5% | +6.3% |
| Jan 7 | TD Cowen | Maintains | Hold → Hold | — | $19.31 | $19.15 | -0.8% | +3.5% | -0.1% | +6.0% | +2.5% | +6.3% |
| Dec 22 | Canaccord Genuity | Maintains | Buy → Buy | — | $16.05 | $16.05 | +0.0% | +5.5% | +2.8% | +4.0% | +2.7% | +0.6% |
| Dec 15 | Barclays | Maintains | Overweight → Overweight | — | $15.46 | $16.02 | +3.6% | +1.9% | +1.6% | +1.9% | +3.5% | +3.8% |
| Dec 11 | Citigroup | Downgrade | Buy → Neutral | — | $17.53 | $16.98 | -3.1% | -5.6% | -11.8% | -10.1% | -10.4% | -10.2% |
| Dec 2 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $18.08 | $17.83 | -1.4% | -0.8% | -1.2% | +0.4% | -1.7% | -3.4% |
| Nov 11 | Piper Sandler | Maintains | Neutral → Neutral | — | $17.08 | $17.00 | -0.5% | -2.9% | -2.3% | -4.3% | -7.0% | -8.1% |
| Nov 7 | UBS | Maintains | Neutral → Neutral | — | $13.00 | $14.31 | +10.1% | +17.3% | +31.4% | +27.6% | +28.4% | +25.8% |
| Nov 7 | JP Morgan | Maintains | Neutral → Neutral | — | $13.00 | $14.31 | +10.1% | +17.3% | +31.4% | +27.6% | +28.4% | +25.8% |
| Nov 7 | Barclays | Maintains | Overweight → Overweight | — | $13.00 | $14.31 | +10.1% | +17.3% | +31.4% | +27.6% | +28.4% | +25.8% |
| Nov 7 | Canaccord Genuity | Maintains | Buy → Buy | — | $13.00 | $14.31 | +10.1% | +17.3% | +31.4% | +27.6% | +28.4% | +25.8% |
| Aug 12 | Morgan Stanley | Maintains | Overweight → Overweight | — | $12.31 | $12.50 | +1.5% | +4.1% | +10.2% | +7.6% | +8.5% | +9.3% |
| Aug 8 | UBS | Maintains | Neutral → Neutral | — | $12.80 | $14.49 | +13.2% | -4.0% | -3.8% | +0.1% | +6.0% | +3.4% |
| Aug 8 | Barclays | Maintains | Overweight → Overweight | — | $12.80 | $14.49 | +13.2% | -4.0% | -3.8% | +0.1% | +6.0% | +3.4% |
| Jun 26 | BofA Securities | Maintains | Neutral → Neutral | — | $11.66 | $11.65 | -0.1% | +0.3% | +0.6% | -0.7% | +3.4% | +11.6% |
| Jun 24 | Barclays | Maintains | Overweight → Overweight | — | $10.79 | $11.01 | +2.0% | +0.9% | +8.1% | +8.4% | +8.7% | +7.3% |
| May 19 | Morgan Stanley | Maintains | Overweight → Overweight | — | $9.39 | $9.12 | -2.9% | -4.9% | -3.3% | -11.4% | -9.1% | -13.0% |
| May 15 | Stephens & Co. | Maintains | Overweight → Overweight | — | $9.12 | $9.01 | -1.2% | +0.9% | +3.0% | -2.1% | -0.4% | -8.8% |
| May 13 | UBS | Maintains | Neutral → Neutral | — | $9.49 | $9.61 | +1.3% | +1.7% | -3.9% | -3.1% | -1.1% | -5.9% |
| May 12 | Goldman Sachs | Maintains | Sell → Sell | — | $8.77 | $9.30 | +6.0% | +8.2% | +10.0% | +4.0% | +4.9% | +7.1% |
| May 12 | Canaccord Genuity | Maintains | Buy → Buy | — | $8.77 | $9.30 | +6.0% | +8.2% | +10.0% | +4.0% | +4.9% | +7.1% |
| May 9 | JP Morgan | Maintains | Neutral → Neutral | — | $8.63 | $9.71 | +12.5% | +1.6% | +10.0% | +11.8% | +5.7% | +6.6% |
| Apr 10 | Barclays | Maintains | Overweight → Overweight | — | $8.67 | $8.29 | -4.4% | -11.2% | -7.6% | -4.5% | -5.9% | -7.4% |
| Mar 4 | Citigroup | Maintains | Buy → Buy | — | $9.85 | $9.49 | -3.7% | +6.8% | +11.0% | +16.4% | +18.8% | +7.5% |
| Feb 14 | Barclays | Maintains | Overweight → Overweight | — | $11.94 | $12.01 | +0.6% | +3.2% | +1.1% | +1.3% | -3.2% | -8.7% |
| Feb 14 | Morgan Stanley | Maintains | Overweight → Overweight | — | $11.94 | $12.01 | +0.6% | +3.2% | +1.1% | +1.3% | -3.2% | -8.7% |
| Feb 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $12.00 | $11.15 | -7.1% | -0.5% | +2.7% | +0.6% | +0.8% | -3.7% |
| Feb 13 | JP Morgan | Maintains | Neutral → Neutral | — | $12.00 | $11.15 | -7.1% | -0.5% | +2.7% | +0.6% | +0.8% | -3.7% |
| Feb 13 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $12.00 | $11.15 | -7.1% | -0.5% | +2.7% | +0.6% | +0.8% | -3.7% |
| Feb 13 | Citigroup | Maintains | Buy → Buy | — | $12.00 | $11.15 | -7.1% | -0.5% | +2.7% | +0.6% | +0.8% | -3.7% |
| Feb 13 | Stifel | Maintains | Buy → Buy | — | $12.00 | $11.15 | -7.1% | -0.5% | +2.7% | +0.6% | +0.8% | -3.7% |
| Feb 13 | UBS | Maintains | Neutral → Neutral | — | $12.00 | $11.15 | -7.1% | -0.5% | +2.7% | +0.6% | +0.8% | -3.7% |
| Feb 10 | Barclays | Maintains | Overweight → Overweight | — | $14.25 | $13.43 | -5.8% | -15.4% | -17.1% | -15.8% | -16.2% | -13.5% |
| Jan 13 | Morgan Stanley | Maintains | Overweight → Overweight | — | $15.58 | $16.40 | +5.3% | +0.8% | -0.9% | -3.9% | -3.1% | -3.2% |
| Nov 1 | Barclays | Maintains | Overweight → Overweight | — | $16.03 | $16.23 | +1.2% | +1.9% | +4.7% | +8.2% | +3.6% | +0.9% |
| Oct 30 | Citigroup | Maintains | Buy → Buy | — | $15.79 | $15.36 | -2.7% | +4.4% | +1.5% | +3.4% | +6.3% | +9.8% |
| Oct 30 | UBS | Maintains | Neutral → Neutral | — | $15.79 | $15.36 | -2.7% | +4.4% | +1.5% | +3.4% | +6.3% | +9.8% |
| Oct 30 | JP Morgan | Maintains | Neutral → Neutral | — | $15.79 | $15.36 | -2.7% | +4.4% | +1.5% | +3.4% | +6.3% | +9.8% |
| Oct 30 | Goldman Sachs | Maintains | Sell → Sell | — | $15.79 | $15.36 | -2.7% | +4.4% | +1.5% | +3.4% | +6.3% | +9.8% |
No insider trades available.
Data updated apr 27, 2026 6:15am
· Source: massive.com